A peptide is just a chain of amino acids.
So how can one peptide affect appetite while another affects growth, blood pressure, inflammation, or digestion?
The peptide itself doesn’t “know” what to do.
Instead, biology works through molecular recognition.
Peptides interact with specific proteins called receptors. Those receptors then tell cells how to respond.
This receptor system is one of the main reasons relatively small differences in peptide structure can produce completely different biological effects.
It also helps explain why scientists spend so much time studying which receptors an experimental peptide activates.
Think of Peptides as Messages
A simple analogy is to think of a peptide as a message.
The message travels until it encounters something capable of reading it.
That reader is the receptor.
Cells contain many different receptor types. Some sit on the cell surface, while others are found inside cells.
Many peptide hormones communicate through receptors located in the cell membrane because peptide molecules generally do not pass freely through lipid membranes.
When the peptide binds to the appropriate receptor, the receptor changes its behavior and starts a signaling process inside the cell.
What Is a Receptor?
A receptor is a protein capable of recognizing particular molecules.
The molecule that binds to a receptor is often called a ligand.
A ligand can be:
- a natural hormone
- a neurotransmitter
- a drug
- an experimental molecule.
The fit isn’t always as simple as a rigid key sliding into one lock.
Both the receptor and ligand are flexible molecular structures.
Binding depends on multiple chemical interactions, including shape, charge, hydrogen bonding, and hydrophobic interactions.
Small changes in a peptide can therefore change how well it interacts with a receptor.
What Happens After a Peptide Binds?
Binding is only the beginning.
An activating ligand can change the shape of the receptor.
That change can then be detected on the inside of the cell.
The receptor may activate other proteins, which activate additional molecules, creating a signaling cascade.
This is how a signal outside the cell can change activity inside it.
One peptide-receptor interaction can eventually affect:
- enzyme activity
- ion channels
- gene expression
- hormone secretion
- metabolism.
The exact response depends on the receptor and cell type.
One Important Receptor Family Is GPCRs
Many peptide hormones signal through G-protein-coupled receptors, usually abbreviated GPCRs.
GPCRs are a huge family of cell-surface receptors involved in many physiological systems and are major targets in drug research.
The general structure includes seven sections that cross the cell membrane.
The outside portion recognizes a ligand.
The inside portion interacts with signaling proteins.
When the receptor is activated, information is transmitted from one side of the membrane to the other.
Some Peptide Hormone Receptors Belong to Class B1
The receptors for several important peptide hormones belong to a GPCR subgroup called class B1.
This family includes receptors for hormones such as:
- GLP-1
- GIP
- glucagon
- parathyroid hormone
- calcitonin.
Class B GPCRs contain a relatively large extracellular region that helps recognize peptide hormones, along with seven membrane-spanning helices involved in receptor activation.
The GLP-1 receptor is one of the best-known members of this group.
GLP-1 Provides an Easy Example
GLP-1 is a naturally occurring peptide hormone.
It binds to GLP-1R, the GLP-1 receptor.
GLP-1R is a class B GPCR involved in glucose homeostasis, gastric function, and food-intake regulation.
When GLP-1 binds to GLP-1R, the receptor activates intracellular signaling.
One major pathway involves a signaling molecule called cAMP.
What Is cAMP?
cAMP stands for cyclic adenosine monophosphate.
It is sometimes called a second messenger.
The peptide hormone is the first message outside the cell.
The receptor receives that signal and causes intracellular cAMP levels to change.
cAMP then helps transmit the signal deeper inside the cell.
GLP-1R commonly signals through a stimulatory G protein called Gs, which activates adenylyl cyclase and increases cAMP production.
That is why researchers often measure cAMP when testing whether an experimental peptide activates receptors such as GLP-1R.
What Does “Agonist” Mean?
A molecule that activates a receptor is called an agonist.
If a peptide binds to GLP-1R and causes the receptor to signal, it can be described as a GLP-1 receptor agonist.
But agonists can differ.
One might activate a receptor very strongly at a low concentration.
Another may require much more material to produce the same response.
Another might activate the receptor but never produce the full maximum response.
That is why scientists measure more than just whether something binds.
What Is a Full Agonist?
A full agonist is capable of producing the maximum response available in a particular experimental receptor system.
A partial agonist activates the same receptor but produces a lower maximum response under those conditions.
This distinction can be important.
Two molecules might bind the same receptor but cause different amounts of downstream signaling.
So receptor pharmacology involves at least two questions:
Does it bind?
and
What happens after it binds?
What Does Potency Mean?
Potency describes how much of a compound is required to produce a particular response.
Scientists often measure this using EC50.
EC50 is the concentration that produces 50% of the maximum measured effect in a particular assay.
A lower EC50 usually means a compound is more potent in that experimental system.
But EC50 values depend on how the experiment was performed.
Cell type, receptor abundance, assay conditions, and other factors can affect the number.
So an EC50 isn’t a universal score for how “strong” a peptide is.
One Peptide Can Sometimes Activate More Than One Receptor
This is where modern peptide engineering gets especially interesting.
Natural peptide hormones can belong to related molecular families.
Their receptors may also be structurally related.
Scientists can sometimes modify one peptide so that it activates several related receptors.
These are called multi-receptor agonists or polyagonists.
Recent metabolic peptide research has focused heavily on the related receptors for:
- GLP-1
- GIP
- glucagon.
These are class B1 GPCRs with related structural and signaling characteristics.
Tirzepatide Is a Dual-Receptor Example
Tirzepatide activates two receptors:
GIPR + GLP-1R
That makes it a dual agonist.
One engineered molecule can interact with both receptor systems.
This is different from mixing two completely separate drugs together.
The receptor profile is built into one molecule.
Retatrutide Goes One Step Further
Retatrutide, also known as LY3437943, is an investigational engineered peptide that activates three receptors:
GIPR + GLP-1R + GCGR
That makes it a triple receptor agonist.
Structural studies have directly visualized retatrutide interacting with all three receptor complexes and examined how different parts of the peptide contact GLP-1R, GIPR, and GCGR.
For laboratory scientists studying the molecule’s chemistry or receptor pharmacology, a retatrutide research peptide is a research reagent rather than an approved medicine or Lilly’s clinical-trial material.
As of September 2026, Lilly states that retatrutide remains investigational and is not FDA approved.
How Can One Peptide Fit Three Receptors?
The three receptors are related.
They aren’t identical, but they share structural features.
Researchers can engineer the peptide sequence so that different amino-acid side chains make useful contacts with all three receptor systems.
Cryo-electron microscopy has allowed scientists to see these receptor-peptide complexes in remarkable detail.
Researchers studying retatrutide found both common and receptor-specific interactions when the molecule was bound to GLP-1R, GIPR, and GCGR.
This helps explain how one peptide can activate several related receptors without those receptors being exactly the same.
Does Retatrutide Activate All Three Equally?
No.
This is another important point.
“Triple agonist” means the molecule can activate three receptors.
It does not mean the three activities are equally potent.
Retatrutide has a distinct potency profile across GIPR, GLP-1R, and GCGR.
The balance between these receptor activities is part of the pharmacological design.
Modern reviews of class B1 GPCRs emphasize that multifunctional agonists can be engineered with different activity profiles across related metabolic receptors.
Why Would Scientists Want Multiple Receptors?
Different receptors can contribute different biological signals.
GLP-1R and GIPR are both involved in incretin and metabolic signaling.
GCGR has important effects involving liver metabolism, glucose regulation, amino-acid metabolism, and energy balance.
Researchers are interested in whether combining these pathways can produce a useful overall response that differs from targeting just one receptor.
That is the scientific idea behind polyagonism.
It is not simply:
three receptors must be three times better.
Biology doesn’t work that neatly.
More Receptors Can Also Mean More Complexity
Every additional receptor creates another set of questions.
Researchers need to determine:
- how strongly the molecule activates it
- which tissues express the receptor
- what downstream signals are produced
- how much peptide reaches those tissues
- whether the combined signaling creates unexpected effects.
A molecule that activates several receptors can therefore be more difficult to understand than a selective single-receptor agonist.
This is part of what makes modern polyagonist research scientifically interesting.
Do All Cells Have the Same Receptors?
No.
Different tissues express different sets and amounts of receptors.
A peptide circulating throughout the body therefore does not necessarily produce the same effect everywhere.
A cell that does not express the relevant receptor may barely respond to the peptide at all.
Another cell with abundant receptor expression may respond much more strongly.
This is one reason a peptide can produce relatively specific biological effects even though it may travel through many parts of the body.
The receptor distribution helps determine where the message can be read.
Can a Receptor Produce Different Signals From Different Ligands?
Yes.
This is one of the more advanced ideas in receptor pharmacology.
Two molecules can activate the same receptor but sometimes favor different signaling pathways or receptor behaviors.
This is often discussed under terms such as biased agonism or biased signaling.
GPCR researchers study whether different ligands change receptor interactions, internalization, G-protein signaling, arrestin signaling, or other pathways in distinct ways. GLP-1R research has been particularly useful for investigating these concepts.
So even saying:
Both molecules activate GLP-1R
does not automatically mean they are biologically identical.
Receptors Can Also Move
Cell-surface receptors are not necessarily fixed in one location forever.
After activation, some GPCRs can be internalized into the cell.
They may then:
- continue signaling
- be recycled back to the cell surface
- be degraded.
This process is called receptor trafficking.
Modern research into GLP-1R, GIPR, and GCGR considers not only receptor activation but also how receptors move and signal after ligand binding.
This adds another layer to peptide pharmacology.
Why Does Peptide Shape Matter?
A peptide isn’t usually a straight string floating rigidly in space.
It can adopt three-dimensional shapes.
When it interacts with a receptor, particular amino acids need to be positioned appropriately.
Class B peptide hormone receptors use a coordinated recognition mechanism involving the extracellular receptor domain and the transmembrane region. Structural studies show that the peptide’s C-terminal region helps establish binding while the N-terminal portion engages deeper in the receptor to promote activation.
This is why changing even one amino acid can sometimes change receptor activity dramatically.
How Do Scientists Study Receptors?
Researchers use several approaches.
Cell Assays
Scientists can grow cells engineered to express a particular receptor.
They add different concentrations of a peptide and measure signals such as cAMP.
Binding Studies
These experiments ask how strongly a ligand associates with a receptor.
Mutational Studies
Researchers change individual amino acids in the receptor to see which regions are important for peptide recognition.
Structural Biology
Cryo-electron microscopy and related methods can show receptor-ligand complexes in three dimensions.
The retatrutide structural study is a good example. Researchers examined the peptide bound to each of its three intended receptor systems.
Why Material Quality Matters in These Experiments
Imagine researchers are trying to calculate the concentration at which a peptide produces half-maximal receptor activation.
That experiment depends on knowing what material is actually present.
If the peptide:
- is partly degraded
- contains significant impurities
- has uncertain identity
- has an inaccurate concentration
the resulting potency estimate may be misleading.
This is why peptide-receptor research often relies on analytical characterization alongside biological assays.
The receptor experiment tells scientists what the peptide does.
Analytical chemistry helps establish what peptide they actually tested.
Receptor Activity Does Not Tell You Whether Something Is Safe
This distinction is worth emphasizing.
A compound can activate a receptor beautifully in a laboratory experiment and still be unsuitable as a medicine.
Receptor assays do not establish:
- long-term safety
- clinical effectiveness
- appropriate dose
- toxicity
- pharmaceutical manufacturing quality.
Those questions require additional preclinical and clinical research.
This is especially relevant for investigational molecules such as retatrutide, which remains under Phase 3 development rather than being an approved drug.
Why Receptors Are Such Important Drug Targets
Receptors control major biological processes.
If scientists can understand how to activate, block, or modify receptor signaling selectively, they can potentially influence those processes in predictable ways.
GPCRs in particular have become one of the most important families of drug targets because they regulate so many physiological systems.
Peptide hormones provide natural starting points for understanding many of these receptors.
Researchers can then alter the peptide structure to change:
- potency
- selectivity
- duration
- receptor balance.
That is the basis of a large part of modern peptide pharmacology.
Conclusion
Peptides don’t “know” what biological job to perform.
Their effects come from molecular interactions.
A peptide travels through a biological system and encounters receptors capable of recognizing its structure.
If it activates one of those receptors, the receptor passes the message into the cell through signaling pathways such as cAMP.
Different cells express different receptors.
Different peptides bind different receptors.
And different receptor combinations produce different biological effects.
Modern molecules such as retatrutide show how far scientists can take this idea. Instead of designing a peptide for one receptor, researchers can engineer a single molecule to interact with several related receptor systems.
That makes receptors one of the best starting points for understanding peptide science.
If amino-acid sequence tells us what the peptide is, receptor pharmacology helps tell us what that peptide can do.
References
Hoare SRJ. Structure and mechanism for recognition of peptide hormones by Class B G-protein-coupled receptors.
Yang D, et al. Class B1 GPCRs: insights into multireceptor pharmacology for the treatment of metabolic disease. 2024.
Li W, et al. Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide. Cell Discovery. 2024.
Zhao P, et al. Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors.
